China Biologic Products (NASDAQ:CBPO) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Tuesday.

Several other equities research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 7th. Morgan Stanley cut shares of China Biologic Products from an “overweight” rating to an “equal weight” rating and set a $84.00 price target for the company. in a research report on Monday, November 5th. ValuEngine raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Thursday, November 1st. Finally, Credit Suisse Group cut shares of China Biologic Products from an “outperform” rating to a “neutral” rating in a research report on Monday, August 6th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. China Biologic Products has a consensus rating of “Hold” and a consensus price target of $95.33.

CBPO traded up $2.93 during trading on Tuesday, hitting $72.99. 307,000 shares of the stock traded hands, compared to its average volume of 304,608. The stock has a market capitalization of $2.29 billion, a P/E ratio of 14.75, a PEG ratio of 5.05 and a beta of 1.40. China Biologic Products has a 12-month low of $60.08 and a 12-month high of $107.44.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.96 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.09 by ($0.13). The firm had revenue of $119.10 million for the quarter, compared to analysts’ expectations of $122.00 million. China Biologic Products had a net margin of 15.50% and a return on equity of 11.44%. The company’s quarterly revenue was up 19.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.32 EPS. On average, analysts predict that China Biologic Products will post 3.43 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of CBPO. Gabelli Funds LLC purchased a new stake in shares of China Biologic Products in the 3rd quarter worth about $232,000. Fox Run Management L.L.C. purchased a new stake in shares of China Biologic Products in the 3rd quarter worth about $262,000. Myriad Asset Management Ltd. purchased a new stake in shares of China Biologic Products in the 2nd quarter worth about $348,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of China Biologic Products in the 3rd quarter worth about $352,000. Finally, Parametrica Management Ltd purchased a new stake in shares of China Biologic Products in the 2nd quarter worth about $386,000. 43.58% of the stock is owned by hedge funds and other institutional investors.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Article: Google Finance

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.